Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.52 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.38 |
| ▸ | TUBB | P07437 | 1/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL61008 | 0.81 | ADORA2A (0.49) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL31462939 | 0.78 | ADORA2A (0.58) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL55563 | 0.78 | ADORA2A (0.58) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL24170311 | 0.78 | ADORA2A (0.50) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL19661007 | 0.78 | ADORA2A (0.46) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL5334843 | 0.78 | ADORA2A (0.50) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL30277827 | 0.78 | ADORA2A (0.50) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| Hydrochloric Acid SCHEMBL30277817 | 0.76 | ADORA2A (0.49) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL2876033 | 0.75 | AXL (0.52) | AXLMKNK1MKNK2ADORA2AADORA1 | |
| SCHEMBL15472013 | 0.75 | HTT (0.47) | ADORA2AADORA1HTTMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115746017-B | Thienopyrimidine compound and preparation method and application thereof | 英维沃化工科技(广州)有限公司 | 2024-06-07 | — | — | CN | claimed |
| CN-115746017-A | Thienopyrimidine compound and preparation method and application thereof | 英维沃化工科技(广州)有限公司 | 2023-03-07 | — | — | CN | claimed |
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2026-02-10 | — | — | US | disclosed |
| US-12281126-B2 | Inhibitors of cyclin-dependent kinase 7 and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-04-22 | — | — | US | disclosed |
| CN-112218863-B | O-glycoprotein-2-acetamido-2-deoxy-3-D-pyranoside enzyme inhibitors | 比奥根MA公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-115746017-B | Thienopyrimidine compound and preparation method and application thereof | 英维沃化工科技(广州)有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| CN-113039182-B | Inhibitors of YAP/TAZ-TEAD interactions and their use in cancer treatment | 伊文蒂瓦公司 | 2024-02-20 | — | — | CN | disclosed |
| US-20230399302-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS | NATIONAL INSTITUTES OF HEALTH | 2023-12-14 | — | — | US | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | THE UNIVERSITY OF LIVERPOOL (GB) | 2023-11-02 | — | — | US | disclosed |
| WO-2007056215-A2 | N-ARYL-THIENOPYRIMIDIN-4-AMINES AND THE USE THEREOF | CYTOVIA, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CYTOVIA, INC. (US) | 2007-05-03 | — | — | US | disclosed |
| WO-2006072831-A1 | PYRROLOPYRAZOLES, POTENT KINASE INHIBITORS | PFIZER INC. (US) | 2006-07-13 | — | — | WO | disclosed |
| EP-1192164-B1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2005-08-17 | — | — | EP | disclosed |
| US-6787541-B1 | MOVEMENT DISORDERS, PARKINSON'S DISEASE | VERNALIS RESEARCH LIMITED (GB) | 2004-09-07 | — | — | US | disclosed |
| EP-1192164-A1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2002-04-03 | — | — | EP | disclosed |
| WO-2001002409-A1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2001-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545675-B2 | Anti-wolbachia pyrido[2,3-d]pyrimidine compounds | CBR1, CBR3, COX6C | AXL 975/4885MKNK1 4150/4885MKNK2 3896/4885 |
| US-20230348460-A1 | ANTI-WOLBACHIA PYRIDO[2,3-d]PYRIMIDINECOMPOUNDS | PWWP2B, WARS1, PNPO | AXL 1305/4885MKNK1 2051/4885MKNK2 2028/4885 |
| US-12281126-B2 | Inhibitors of cyclin-dependent kinase 7 and uses thereof | CDK9, CDK7, CDK1 | AXL 1342/4885MKNK1 189/4885MKNK2 215/4885 |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | AXL 1317/4885MKNK1 286/4885MKNK2 293/4885 |
| US-20230399302-A1 | PROCESS FOR THE PREPARATION OF HETEROARYL-SUBSTITUTED SULFUR(VI) COMPOUNDS | TST, TYR, STS | AXL 1214/4885MKNK1 1924/4885MKNK2 1461/4885 |
| US-20070099877-A1 | N-aryl-thienopyrimidin-4-amines and analogs as activators of caspases and inducers of apoptosis and the use thereof | CASP4, CASP3, API5 | AXL 1452/4885MKNK1 2048/4885MKNK2 1723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.